• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

作者信息

Inzucchi Silvio E, Bergenstal Richard M, Buse John B, Diamant Michaela, Ferrannini Ele, Nauck Michael, Peters Anne L, Tsapas Apostolos, Wender Richard, Matthews David R

机构信息

Section of Endocrinology, Yale University School of Medicine, Yale-New Haven Hospital, New Haven, CT, USA.

出版信息

Diabetologia. 2015 Mar;58(3):429-42. doi: 10.1007/s00125-014-3460-0. Epub 2015 Jan 13.

DOI:10.1007/s00125-014-3460-0
PMID:25583541
Abstract
摘要

相似文献

1
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.2015年2型糖尿病高血糖管理：以患者为中心的方法。美国糖尿病协会和欧洲糖尿病研究协会立场声明的更新版
Diabetologia. 2015 Mar;58(3):429-42. doi: 10.1007/s00125-014-3460-0. Epub 2015 Jan 13.
2
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2型糖尿病高血糖管理：以患者为中心的方法。美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）的立场声明。
Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0. Epub 2012 Apr 20.
3
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):193-4. doi: 10.2337/dc06-2060.
4
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):193; author reply 194-6. doi: 10.2337/dc06-1828.
5
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):190-2; author reply 194-6. doi: 10.2337/dc-06-1670.
6
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetes Care. 2007 Jan;30(1):192-3; author reply 194-6. doi: 10.2337/dc06-1858.
7
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al.2型糖尿病高血糖的医学管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明：对纳坦等人的回应
Diabetes Care. 2009 Mar;32(3):e35-6; author reply e37-8. doi: 10.2337/dc08-2275.
8
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al.2型糖尿病高血糖的医学管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明：对纳坦等人的回应
Diabetes Care. 2009 Mar;32(3):e34; author reply e37-8. doi: 10.2337/dc08-2093.
9
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖的医学管理：治疗起始与调整的共识算法：美国糖尿病协会和欧洲糖尿病研究协会的共识声明
Diabetologia. 2009 Jan;52(1):17-30. doi: 10.1007/s00125-008-1157-y. Epub 2008 Oct 22.
10
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.2型糖尿病高血糖管理：治疗起始与调整的共识算法。美国糖尿病协会和欧洲糖尿病研究协会的共识声明。
Diabetologia. 2006 Aug;49(8):1711-21. doi: 10.1007/s00125-006-0316-2.

引用本文的文献

1
Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials.维格列汀与其他二肽基肽酶4（DPP-4）抑制剂治疗2型糖尿病的疗效和安全性：随机对照试验的系统评价
Cureus. 2025 Sep 1;17(9):e91432. doi: 10.7759/cureus.91432. eCollection 2025 Sep.
2
Odor olfactory dysfunction in chronic kidney disease and diabetes mellitus and its association with nutritional factors.慢性肾脏病和糖尿病中的嗅觉功能障碍及其与营养因素的关联。
Caspian J Intern Med. 2025 Mar 21;16(2):289-296. doi: 10.22088/cjim.16.2.289. eCollection 2025 Spring.
3

本文引用的文献

1
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.胰高血糖素样肽-1 受体激动剂与基础胰岛素联合治疗 2 型糖尿病的系统评价和荟萃分析。
Lancet. 2014 Dec 20;384(9961):2228-34. doi: 10.1016/S0140-6736(14)61335-0. Epub 2014 Sep 11.
2
High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7).高谷氨酸脱羧酶自身抗体（GADA）滴度增加成人隐匿性自身免疫性糖尿病（LADA）患者胰岛素治疗需求风险：一项7年随访研究（NIRAD研究7）
Eur J Endocrinol. 2014 Dec;171(6):697-704. doi: 10.1530/EJE-14-0342. Epub 2014 Sep 11.
3
Drug utilization pattern among type II diabetic patients in Palestine.
巴勒斯坦II型糖尿病患者的药物使用模式。
BMC Health Serv Res. 2025 Jul 2;25(1):891. doi: 10.1186/s12913-025-13028-6.
4
Triglyceride-Glucose Index and Atherogenic Index as Alternative Biomarkers for Glycemic Control in Type 2 Diabetes Mellitus.甘油三酯-葡萄糖指数和致动脉粥样硬化指数作为2型糖尿病血糖控制的替代生物标志物
Cureus. 2025 Mar 31;17(3):e81550. doi: 10.7759/cureus.81550. eCollection 2025 Mar.
5
Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups: a Systematic Review and Meta-analysis of Observational Studies.跨种族和民族群体开具钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）和胰高血糖素样肽-1受体激动剂（GLP-1 RA）的循证实践：观察性研究的系统评价和荟萃分析
J Racial Ethn Health Disparities. 2025 Apr 21. doi: 10.1007/s40615-025-02410-z.
6
Effect of physical activity counselling on the number of contacts in primary healthcare, specialised healthcare and the related healthcare costs among patients with type 2 diabetes: a register-based evaluation study.体育活动咨询对2型糖尿病患者在初级医疗保健、专科医疗保健中的就诊次数及相关医疗费用的影响：一项基于登记的评估研究。
BMJ Public Health. 2023 Oct 25;1(1):e000098. doi: 10.1136/bmjph-2023-000098. eCollection 2023 Nov.
7
Type 2 Diabetes, Obesity and Their Relation to the Risks of Thyroid Cancer.2型糖尿病、肥胖及其与甲状腺癌风险的关系。
Physiol Res. 2024 Dec 31;73(6):1025-1035. doi: 10.33549/physiolres.935433.
8
Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study.基于恩格列净的2型糖尿病四重口服疗法：一项前瞻性队列研究。
Sci Rep. 2025 Jan 9;15(1):1427. doi: 10.1038/s41598-024-84993-x.
9
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson's Disease.靶向葡萄糖代谢：帕金森病的一种新治疗方法。
Cells. 2024 Nov 13;13(22):1876. doi: 10.3390/cells13221876.
10
Amputation versus circular external fixation in the treatment of diabetic foot with osteomyelitis: a cost and quality-of-life analysis.截肢与环形外固定治疗糖尿病足合并骨髓炎的成本与生活质量分析
Ther Adv Endocrinol Metab. 2024 Oct 7;15:20420188241271795. doi: 10.1177/20420188241271795. eCollection 2024.
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
心力衰竭、沙格列汀和糖尿病：来自 SAVOR-TIMI 53 随机试验的观察结果。
Circulation. 2014 Oct 28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389. Epub 2014 Sep 4.
4
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.利司那肽联合基础胰岛素治疗2型糖尿病患者：一项荟萃分析。
J Diabetes Complications. 2014 Nov-Dec;28(6):880-6. doi: 10.1016/j.jdiacomp.2014.07.007. Epub 2014 Jul 18.
5
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂通过增加糖尿改变肾小管尿酸转运活性来降低血清尿酸水平。
Biopharm Drug Dispos. 2014 Oct;35(7):391-404. doi: 10.1002/bdd.1909. Epub 2014 Aug 6.
6
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.胰高血糖素样肽 1 受体激动剂或速效胰岛素联合优化基础胰岛素治疗 2 型糖尿病。
Diabetes Care. 2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876. Epub 2014 Jul 10.
7
A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population.一项关于在印度人群中寻找吡格列酮与膀胱癌发病率相关性的回顾性研究。
Indian J Endocrinol Metab. 2014 May;18(3):425-7. doi: 10.4103/2230-8210.131223.
8
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.在肥胖且血糖控制不佳的 2 型糖尿病患者中，加用恩格列净可改善血糖控制，减少胰岛素用量，且不增加低血糖风险。
Diabetes Care. 2014 Jul;37(7):1815-23. doi: 10.2337/dc13-3055. Epub 2014 Jun 14.
9
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).卡格列净对2型糖尿病患者血清电解质的影响与估算肾小球滤过率（eGFR）的关系。
Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22.
10
LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes.LADA 和 CARDS：一项前瞻性研究，旨在观察已确诊的成年起病自身免疫性糖尿病的临床转归。
Diabetes Care. 2014 Jun;37(6):1643-9. doi: 10.2337/dc13-2383. Epub 2014 Apr 10.